2 news items
Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
ITCI
18 Jun 24
of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to be materially
Intra-Cellular Therapies Reports First Quarter 2024 Financial Results
ITCI
7 May 24
release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks
- Prev
- 1
- Next